SYDNEY, Australia, Oct. 4 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis today announced that it had contracted Allertec Hellas SA to market and distribute its asthma diagnostic and management tool, Aridol, in Greece. Pharmaxis is awaiting marketing authorisation for Aridol in Europe.
Dr Alan Robertson, Pharmaxis CEO said “The agreement with Allertec further extends our reach in Europe, following the earlier announcement of our partners in Scandinavia and Switzerland. Allertec will be a great new partner and they were selected on the basis of their complimentary range of respiratory products, excellent local knowledge and the dedicated resources they can commit to making Aridol a success.”
Andriana Georgiou, Allertec President and Managing Director said: “Aridol is a unique drug for the Greek market and fits very well with our specialist respiratory and allergy focus. Further to its diagnostic indications, we aim to establish Aridol as an asthma management tool, and look forward to working with Pharmaxis and contributing to the overall success of Aridol in the territory.”
Pharmaxis lodged its application for regulatory and marketing approval of Aridol with the Swedish Medical Products Agency (MPA) in May 2005, and anticipates registration for Aridol in 2006. Following Swedish registration, Pharmaxis will seek approval of Aridol in the 27 other European member states via the mutual recognition procedure. Greece is expected to be amongst the first.
To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .
Forward-Looking Statements
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this press release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We can not guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the “Risk Factors and Other Uncertainties” section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.
Contact: Alan Robertson Chief Executive Officer Tel: +61-2-9454-7200 Fax: +61-2-9451-3622 Released through: United States: Brandon Lewis Trout Group Tel: +1-212-477-9007 Email: blewis@troutgroup.com Australia: Ashley Rambukwella Financial & Corporate Relations Pty Ltd. Tel: +61-2-8264-1004 or +61-407-231-282 Email: a.rambukwella@fcr.com.au
Pharmaxis Ltd
CONTACT: Alan Robertson of Pharmaxis, +61-2-9454-7200 or fax,+61-2-9451-3622; or Brandon Lewis of Trout Group for Pharmaxis,+1-212-477-9007, or blewis@troutgroup.com; or Ashley Rambukwella ofFinancial & Corporate Relations Pty Ltd. for Pharmaxis, +61-2-8264-1004, or+61-407-231-282, or a.rambukwella@fcr.com.au
Web site: http://www.pharmaxis.com.au/
